Finch Therapeutics (Boston) Relies on CentraXX for the Exploration of New Scientific Frontiers.

Although medical research is currently deeply engaged in the study of human microbiomes, it is still a long way from a real understanding. Biopharmaceutical companies such as Finch Therapeutics Inc., based in Summerville, USA, are working to increase knowledge in the field of diarrhoea, for example.

4 billion people affected and 7.5 million deaths worldwide each year

Diarrhoea can be a symptom of many diseases (e.g. infections, food poisoning, tumors). An estimated 4 billion people worldwide suffer from diarrhoea every year. 7.5 million people (especially children) die as a result.

Finch Therapeutics is active in the production of biotherapeutics from stool grafts for the treatment of chronic intestinal diseases (diarrhoea).

Under the leadership of Mark Smith, the team behind the young biopharmaceutical company, some 200-strong, has attracted impressive attention worldwide through the research and development of modern therapies with the help of human intestinal microbes and successfully completed a financing call in the amount of 36 million US dollars at the beginning of 2018.

In the search for a suitable Clinical Trial Management System (CTMS), which replaces Finch’s current landscape of various individual systems ranging from paper-based documentation to various standard IT solutions with a central IT system, the Americans decided in favor of the KAIROS product “CentraXX CTMS”.

CentraXX – Data protection made in Germany

In addition to the draw of implementing a centralized system, CentraXX also impressed Finch with its comprehensive data security, including the dedicated rights and roles concept and the ability to reliably separate personal identifying data from non-personal identifying data.

The system is scheduled to go live in September 2018, following training sessions for Finch employees by KAIROS GmbH in the use of XML and BIRT.

As its first step, Finch will use CentraXX CTMS for subject management (infiltration/administration), after which Finch will use CentraXX CTMS to support the SOP-controlled production of personalized – i.e. individual, tailor-made – drugs. CentraXX CTMS is – through the use of the CentraXX Validation Kit – an essential component of a valid overall system solution for which the company is seeking FDA approval.